A phase III study of M801801 in plaque psoriasis patients

Trial Profile

A phase III study of M801801 in plaque psoriasis patients

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Betamethasone butyrate propionate/maxacalcitol (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Maruho
  • Most Recent Events

    • 28 Mar 2016 According to a company media release, Chugai has acquired the marketing approval of "Marduox Ointment" (Marduox) for the indication of psoriasis vulgaris, which has been jointly developed by Chugai and Maruho.
    • 27 May 2015 New trial record
    • 25 May 2015 Chugai Pharmaceutical has submitted a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare for a combination topical drug preparation of maxacalcitol and betamethasone butyrate propionate based on the data from this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top